Lithium: the pharmacodynamic actions of the amazing ion
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Lithium has been used for the treatment of mood disorders for over 60 years, yet the exact mechanisms by which it exerts its therapeutic effects remain unclear. Two enzymatic chains or pathways emerge as targets for lithium: inositol monophosphatase within the phosphatidylinositol signalling pathway and the protein kinase glycogen synthase kinase 3. Lithium inhibits these enzymes through displacing the normal cofactor magnesium, a vital regulator of numerous signalling pathways. Here we provide an overview of evidence, supporting a role for the inhibition of glycogen synthase kinase 3 and inositol monophosphatase in the pharmacodynamic actions of lithium. We also explore how inhibition of these enzymes by lithium can lead to downstream effects of clinical relevance, both for mood disorders and neurodegenerative diseases. Establishing a better understanding of lithium’s mechanisms of action may allow the development of more effective and more tolerable pharmacological agents for the treatment of a range of mental illnesses, and provide clearer insight into the pathophysiology of such disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in healthcare, many drugs for which the mechanism of action is unknown are trusted due to years of use that illustrate high efficacy and a clean safety profile (e.g., lithium14).”
From Machine intelligence in healthcare—perspectives on trustworthiness, explainability, usability, and transparency (2020) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244 · cited 10×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialInositol phosphates and cell signalling
Berridge, M. J., & Irvine, R. F. (1989) · Nature · doi:10.1038/341197a0 · Cited by 4,058
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301 · cited 6×
“Direct and indirect inhibition of GSK3 by lithium In 1996, two independent studies demonstrated lithium’s effects as a direct inhibitor of GSK3 in vitro and in cells [Klein and Melton, 1996; Stambolic et al. 1996].”
BackgroundInfluentialGSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 2×
“2006] and is primarily regulated through inhibition of its activity via a combination of factors [Kaidanovick-Beilin and Woodgett, 2011], including phosphorylation, intracellular localisation and sequestration by binding proteins [Doble and Woodgett, 2003; Jope and Johnson, 2004; Kockeritz et al. 2006].”
BackgroundThe glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,517 · cited 2×
“2006] and is primarily regulated through inhibition of its activity via a combination of factors [Kaidanovick-Beilin and Woodgett, 2011], including phosphorylation, intracellular localisation and sequestration by binding proteins [Doble and Woodgett, 2003; Jope and Johnson, 2004; Kockeritz et al. 2006].”
BackgroundCohen, P., & Frame, S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096075 · Cited by 1,478 · cited 2×
“…2010], and has a key role in the regulation of a number of cell functions, including insulin receptor signalling, the specification of cell fates during embryonic development, immunity and inflammation responses and neurotransmission [Cohen and Frame, 2001; KaidanovichBeilin and Woodgett, 2011].”
BackgroundLITHIUM SALTS IN THE TREATMENT OF PSYCHOTIC EXCITEMENT
Cade, J. F. J. (1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb36912.x · Cited by 1,463
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410 · cited 2×
“Activation of Akt involves phosphorylation of a regulatory threonine residue (Thr 308) by phosphatidylinositol-dependent kinase 1 (PDK1) and additional phosphorylation of the Ser 473 residue by the PDK2/TORC2 kinase [Alessi and Cohen, 1998; Jacinto et al. 2006], in response to phosphatidylinositol kinase (PI3K)-mediat…”
BackgroundMethodLithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 6×
“…lymphoma/leukaemia 2 (bcl-2) [Chen et al. 1999; Manji et al. 2000a; Moore et al. 2000b], as well as its effects on GSK3 [Klein and Melton, 1996; Stambolic et al. 1996; Chalecka-Franaszek and Chuang, 1999; De Sarno et al. 2002; Beaulieu et al. 2004], is thought to exert major neurotrophic…”
BackgroundInfluentialLithium salts in the treatment of psychotic excitement
Cade, J. F. J. (1999) · Australian and New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.1999.06241.x · Cited by 1,150
Research works printed but not linked: 7
- Bowden C., 2000, J Clin Psychiatry, 61, 35
- Burgess S., 2001, Cochrane Database Syst Rev, CD003013
- Coppen A., 2000, J Clin Psychiatry, 61, 52
- Lenox R., 2000, J Clin Psychiatry, 61, 5
- Li J., 2012, Plos One, 7, 8
- Manji H., 2000, J Clin Psychiatry, 61, 82
- Tondo L., 2000, J Clin Psychiatry, 61, 97
Cited by
Cutillo, C. M., Sharma, K. R., Foschini, L., Kundu, S., Mackintosh, M., Mandl, K. D., MI in Healthcare Workshop Working Group, Beck, T., Collier, E., Colvis, C., et al. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0254-2 · Cited by 337
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
“Diacylglycerate remains bound to the membrane and leads downstream activation of protein kinase C and increases the release of calcium from intracellular stores (Conn and Sanders-Bush, 1984; Brown and Tracy, 2013).”
BackgroundLithium: A review of pharmacology, clinical uses, and toxicity
Oruch, R., Elderbi, M. A., Khattab, H. A., Pryme, I. F., & Lund, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.042 · Cited by 221
Vijay, G. V., Zhao, N., Den Hollander, P., Toneff, M. J., Joseph, R., Pietila, M., Taube, J. H., Sarkar, T. R., Ramirez-Pena, E., Werden, S. J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1125-0 · Cited by 163
“The lithium ion competes with magnesium ions that are required for kinase activity [37, 38].”
BackgroundPharmacological Treatments for Patients with Treatment-Resistant Depression
Ruberto, V. L., Jha, M. K., & Murrough, J. W. (2020) · Pharmaceuticals · doi:10.3390/ph13060116 · Cited by 181
Metadata
- Authors
- Brown, K. M., & Tracy, D. K.
- Affiliations
- King's College London (GB)
- Oxleas NHS Foundation Trust (GB)
- ORCID
- Tracy, Derek K.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-12-21
- Volume
- 3
- Issue
- 3
- Pages
- 163-176
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC3805456
- OpenAlex
- W2131991500
- Cited by
- 140
- References
- 124
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 9 · 2019: 10 · 2018: 10 · 2017: 9 · 2016: 9 · 2015: 18 · 2014: 8 · 2013: 1
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- lithium, pharmacodynamics, glycogen synthase kinase-3, inositol monophosphatase, magnesium cofactor, mood disorders, neurodegenerative diseases, enzyme inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lithium: the pharmacodynamic actions of the amazing ion. https://app.cochat.ai/papers/10.1177/2045125312471963
- The paper
- Brown, K. M., & Tracy, D. K. (2013). Lithium: the pharmacodynamic actions of the amazing ion. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125312471963
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.